In-licensing explained: a path to expanding your portfolio

female colonis employee facing left

In-licensing explained: a path to expanding your portfolio

Pharmaceutical companies share a common goal when expanding their product portfolios: a relentless commitment to addressing an array of medical conditions and unmet patient needs. In-licensing has become a strategic approach for companies looking to meet these objectives, but navigating the in-licensing journey can be a complex venture, leaving many unsure of where to begin. We’re here to guide you through in-licensing, its processes, and why finding the right pharmaceutical partnerships can have a truly transformative impact on your business.

Understanding in-licensing medicines

In-licensing involves acquiring the rights to license a pharmaceutical product that has been developed by another company. Unlike out-licensing, where licenses are granted to external partners, in-licensing focuses on bringing external assets into your portfolio. This approach offers several distinct advantages:

Access to a broader range of products: In-licensing enables your company to add depth to a portfolio speciality or add new portfolio products, enhancing your ability to address a wider range of medical conditions and patient needs.

Accelerated market entry: Instead of dedicating resources to developing a product from scratch, in-licensing facilitates faster market entry by providing access to existing dossiers or licenses. This approach builds on the groundwork laid by the development efforts of pharmaceutical partners, offering a valuable shortcut without the internal commitment risk associated with developing the product independently. This speed is crucial in ensuring that patients receive innovative and value-added treatments as soon as possible and companies can maximise the potential of a new product in market.

Risk mitigation: By in-licensing products that have already undergone development, you can reduce the inherent risks associated with drug discovery, costly development projects and regulatory hurdles by accessing dossiers or licences that are ready for commercialisation.

Market expansion: Pharmaceutical partnerships achieved through in-licensing can provide access to products, therapeutic areas or patient populations that may have previously been outside of your company’s reach.

While there are many benefits of in-licensing, it can be a complex endeavour. That’s why it’s crucial to ensure that you choose the right pharmaceutical partnerships for your portfolio extension.

Navigating the in-licensing landscape

At Colonis, we recognise that successful in-licensing is more than a process; it’s an art refined through experience. Our streamlined approach ensures you get straight to the heart of it:

Market insight: Leverage our market prowess for a comprehensive evaluation, including competitive analysis, pricing insights, and reimbursement considerations.

Thorough due diligence: Rely on our expertise to scrutinise intellectual property, clinical trial data, and regulatory status, ensuring a robust and viable partnership.

Skilful negotiation: Benefit from our seasoned negotiation skills, securing terms that mutually safeguard both parties’ interests.

Seamless integration: Once the agreement is in place, trust us to seamlessly integrate the product into your operations, navigating regulatory compliance and optimising manufacturing processes.

At Colonis, we don’t just guide you through the in-licensing process; we elevate your journey with expertise honed through successful partnerships.

Colonis: Your partner of choice for in-licensing

With Colonis, your in-licensing journey is not just about acquiring products; it’s about forming a mutually beneficial partnership that’s rooted in patient centricity, regulatory excellence, and a shared commitment to long-term success. Here’s how we provide comprehensive support that goes beyond conventional collaboration:

Streamlined market expansion: Our products are already well-established in the UK, which simplifies the process of bringing them to new markets through pharmaceutical partnerships. We have also collaborated with diverse partners in various markets, leveraging our expertise to in-license and successfully introduce a variety of products to those markets. Our proven track record and established presence in the UK, in addition to your local market knowledge, gives us the best opportunity for success. 

Product and market expertise: While our team possess in-depth knowledge of our products, we recognise that our partners offer invaluable insights related to their own markets. This synergy is where our pharmaceutical partnerships truly shine. Together we merge product expertise with market access experience to achieve successful collaboration and maximise product potential.

Regulatory assurance: At Colonis, we go above and beyond to secure marketing access in new territories, ensuring that our in-licensing partners can seamlessly adopt the product into their respective markets and propel its success. Our commitment to regulatory excellence, as exemplified by our successful navigation of the stringent Medicines and Healthcare products Regulatory Agency (MHRA) guidelines in the UK, sets the stage for a smooth and efficient pathway to market. Combined with our in-depth product knowledge and disease area expertise, together, we can maximise product potential.

Patient-centricity at our core: We share our partners’ values and commitment to patient-centricity. We develop medicines designed to directly address patients’ individual needs and preferences, meaning that when you partner with Colonis, you align with a patient-focused approach that enables the highest quality care.

Resource materials and support: Colonis goes the extra mile to make your journey as seamless as possible.  We provide comprehensive product resources and support when partner companies in-license with us, ensuring you have the necessary tools and assistance at every step.

Investing in research and development: At Colonis, we believe in the power of continuous innovation. We continuously invest in research and development for repurposing medicines, fostering a long-term outlook in our pharmaceutical partnerships. When you partner with us, you’re not just collaborating for the present; you’re securing a trusted partner for the future.

Our dedicated team: The Colonis team have a long history of successfully commercialising and managing value-added products. By carrying out meticulous research and data analysis, we identify and understand areas where we can transform existing molecules into valuable medicines.

In-licensing: let’s reach our shared goal, together

In-licensing offers a strategic advantage to pharmaceutical companies by providing access to a broader range of products, accelerating market entry, mitigating risks, and expanding into new markets and therapeutic areas. However, this process is not without its challenges.

At Colonis, our approach goes beyond the conventional, focusing on patient centricity, regulatory excellence, and long-term success. With Colonis, you benefit from streamlined market expansion, product and market expertise, regulatory assurance, and a deep commitment to patient-centric care.

With Colonis as your dedicated partner, we can work towards our shared goal of empowering the lives of patients together.

If you’re interested in exploring pharmaceutical partnerships with Colonis and enhancing your product portfolio, we’d love to hear from you. Please visit our contact page to embark on your in-licensing journey.

GB-CPL-0-036

December 2023

Stay up to date, connect with us on Social Media

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.